Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry. 2. Oktober 2018 Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018. Oncol Res Treat 41 (suppl 4)(P608). Download Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study. Dechow, T., Riera-Knorrenschild, J., Schulz, H., Janssen, J., Chiabudini, M., Koszinowski, S., Potthoff, K., Lang, S., Runkel, E., 2018. Oncol Res Treat 41 (suppl 4)(P912). Weiterlesen Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer. Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018. Oncol Res Treat 41… Weiterlesen